The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy

[1]  E. Jacobsen,et al.  Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines. , 2022, JACC. Heart failure.

[2]  P. Austin,et al.  Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study , 2021, Circulation. Heart failure.

[3]  Chenelle M. C. Joseph.  Symptomatic Hypoglycemia During Treatment with a Therapeutic Dose of Metformin , 2021, The American journal of case reports.

[4]  A. Hung,et al.  Hospitalization for Heart Failure Among Patients With Diabetes Mellitus and Reduced Kidney Function Treated With Metformin Versus Sulfonylureas: A Retrospective Cohort Study , 2021, Journal of the American Heart Association.

[5]  Chun Zhang,et al.  Mechanism and application of metformin in kidney diseases: An update. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[7]  F. Hernandez-Ilizaliturri,et al.  Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma , 2020, Cancer & Metabolism.

[8]  Shannon R. McCurdy,et al.  Symptomatic Heart Failure in Acute Leukemia Patients Treated With Anthracyclines , 2019, JACC. CardioOncology.

[9]  E. Oikonomou,et al.  Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. , 2019, JAMA cardiology.

[10]  M. Vaduganathan,et al.  Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy , 2019, JACC. CardioOncology.

[11]  L. Désaubry,et al.  Updates in Anthracycline-Mediated Cardiotoxicity , 2018, Front. Pharmacol..

[12]  Zhi-an Li,et al.  Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer , 2018, Medicine.

[13]  G. Meléndez-Mier,et al.  Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene , 2018, Journal of Translational Medicine.

[14]  J. Carvalheira,et al.  Metformin and blood cancers , 2018, Clinics.

[15]  Á. Tósaki,et al.  The Cardioprotective Effect of Metformin in Doxorubicin-Induced Cardiotoxicity: The Role of Autophagy , 2018, Molecules.

[16]  F. Girolami,et al.  Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience , 2018, European journal of heart failure.

[17]  W. Barlow,et al.  Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. , 2017, Cancer Research.

[18]  D. Hardie,et al.  The mechanisms of action of metformin , 2017, Diabetologia.

[19]  Robin L. Jones,et al.  Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. , 2017, The Lancet. Oncology.

[20]  G. Tomlinson,et al.  Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Georges,et al.  Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity. , 2016, Annales de cardiologie et d'angeiologie.

[22]  D. McManus,et al.  Mitoxantrone‐Induced Cardiotoxicity in Acute Myeloid Leukemia—A Velocity Vector Imaging Analysis , 2016, Echocardiography.

[23]  Y. Tseng.  Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats , 2016, Anatolian journal of cardiology.

[24]  P. Nathan,et al.  Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis. , 2016, Journal of the National Cancer Institute.

[25]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials , 2015, Journal of Nuclear Cardiology.

[26]  A. Weyman,et al.  Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. , 2015, The American journal of cardiology.

[27]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[28]  L. Ford,et al.  Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders , 2014, Cancer Prevention Research.

[29]  M. Kaminski,et al.  The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas , 2014, Blood Cancer Journal.

[30]  J. Esteve,et al.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013, Journal of the American College of Cardiology.

[31]  D. Pascual-Figal,et al.  Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity. , 2013, Free radical biology & medicine.

[32]  M. Kawasaki,et al.  Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. , 2012, Cardiovascular research.

[33]  Maryam Rameshrad,et al.  Short-term treatment with metformin suppresses toll like receptors (TLRs) activity in isoproterenol-induced myocardial infarction in rat: are AMPK and TLRs connected? , 2012, International immunopharmacology.

[34]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[35]  D. Pascual-Figal,et al.  Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. , 2011, Free radical biology & medicine.

[36]  G. Fonarow,et al.  Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. , 2010, Journal of cardiac failure.

[37]  Darren K Mcguire,et al.  Metformin in Heart Failure This letter is being simultaneously published in 2007 in Diabetes Care and the American Heart Journal. Copyright 2007 by the American Diabetes Association, Inc., and Elsevier. , 2007, Diabetes Care.

[38]  L. Constine,et al.  Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Walley,et al.  Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. , 2006, Cardiovascular research.

[40]  T. Wallimann,et al.  Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. , 2006, Comptes rendus biologies.

[41]  Ross T Tsuyuki,et al.  Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. , 2005, Diabetes care.

[42]  H. Krumholz,et al.  Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.

[43]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[44]  C. Leeuwenburgh,et al.  Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. , 2002, Cancer research.

[45]  S. Wakasugi.  [The cardiotoxicity of anticancer agents]. , 1996, Ryoikibetsu shokogun shirizu.